Faivre J F, Rouanet S, Bril A
SmithKline Beecham Laboratories Pharmaceutiques, Saint-Grégoire, France.
J Cardiovasc Pharmacol. 1998 Apr;31(4):551-7. doi: 10.1097/00005344-199804000-00013.
The modulation of the protein kinase A-activated chloride current (PKA-I[Cl]) may lead to modification of the cardiac action potential shape. The purpose of this study was to evaluate the effects of glibenclamide, tedisamil, dofetilide, E-4031, and BRL-32872 on the PKA-I(Cl). Experiments were conducted by using the patch-clamp technique in guinea pig ventricular myocytes. PKA-I(Cl) was activated by application of 1 microM isoproterenol and was inhibited by 1 microM propranolol, 10 microM acetylcholine, or 1 mM 4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid (SITS). The sulfonylurea receptor inhibitor, glibenclamide, inhibited PKA-I(Cl) at micromolar concentration. Among class III antiarrhythmic agents, tedisamil induced a dose-dependent inhibition of PKA-I(Cl) with a half effective concentration (EC50) of 7.15 microM (Hill coefficient, 0.54). This effect may contribute to action potential widening induced by tedisamil. In contrast, the selective inhibitors of the rapid component of the delayed rectifier K current (I[Kr]), dofetilide, and E-4031, as well as BRL-32872, that blocks I(Kr) and the L-type calcium current, did not significantly affect the amplitude of PKA-I(Cl), even at high concentrations (10-30 microM). These results demonstrate that compounds such as glibenclamide and tedisamil that are known to block the adenosine triphosphate (ATP)-sensitive K current also affect PKA-I(Cl). Furthermore it appears that blockade of PKA-I(Cl) is not a common feature for all class III antiarrhythmic agents.
蛋白激酶A激活的氯电流(PKA-I[Cl])的调节可能会导致心脏动作电位形态的改变。本研究的目的是评估格列本脲、替地沙米、多非利特、E-4031和BRL-32872对PKA-I(Cl)的影响。实验采用膜片钳技术在豚鼠心室肌细胞中进行。PKA-I(Cl)通过应用1 microM异丙肾上腺素激活,并被1 microM普萘洛尔、10 microM乙酰胆碱或1 mM 4-乙酰氨基-4'-异硫氰酸根合芪-2,2'-二磺酸(SITS)抑制。磺脲类受体抑制剂格列本脲在微摩尔浓度下抑制PKA-I(Cl)。在III类抗心律失常药物中,替地沙米对PKA-I(Cl)产生剂量依赖性抑制,半数有效浓度(EC50)为7.15 microM(希尔系数,0.54)。这种作用可能有助于替地沙米诱导的动作电位增宽。相比之下,延迟整流钾电流(I[Kr])快速成分的选择性抑制剂多非利特和E-4031,以及阻断I(Kr)和L型钙电流的BRL-32872,即使在高浓度(10 - 30 microM)下也不会显著影响PKA-I(Cl)的幅度。这些结果表明,已知能阻断三磷酸腺苷(ATP)敏感性钾电流的化合物如格列本脲和替地沙米也会影响PKA-I(Cl)。此外,似乎阻断PKA-I(Cl)并非所有III类抗心律失常药物的共同特征。